The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • THC Global and distribution partner Endoca, continues to build a presence in New Zealand by providing CBD products
  • Unlike Australia, New Zealand, patients can seek a prescription for CBD products just like any other medicine – making New Zealand patients more accessible
  • In June this year, the company launched a CBDinfo platform to provide quality information on CBD products – 100 medical practitioners have since enrolled
  • THC will continue to drive awareness as it prepares to distribute its Australian-made products in New Zealand
  • THC Global’s shares are down 2.56 per cent today, with shares trading at 38 cents each

THC Global continues to build its presence in New Zealand by providing cannabidiol (CBD) products to patients under a distributor agreement with Endoca.

THC and Endoca first announced their exclusive distribution partnership in November 2017. Under the agreement, THC has been distributing its European-based partner’s medicinal hemp products in Australia.

However, the company is building a presence in New Zealand which is reportedly more straightforward compared to Australia.

In Australia, THC has faced regulatory hurdles for the supply of medicinal hemp to patients. In New Zealand, patients can seek a prescription for CBD products just like any other medicine, and without the need for government approvals.

As a result, New Zealand has a larger, immediately accessible patient population compared to Australia.

To provide patients with the best available information on CBD products, THC Global provided financial assistance to DATAPHARM, a New Zealand healthcare company, to launch CBDinfo.co.nz.

CBDinfo provides medical practitioners evidenced information about the use, availability, and potential benefits and risk of using CBD products.

Since the launch in June 2019, over 100 medical practitioners have enrolled.

THC Global is committed to providing New Zealand prescribers access to high-quality information and guidance on CBD products, including Endoca’s.

So far, initial sales of Endoca’s CBD products have been positive which can be largely attributed to THC funding educational events to drive awareness of Endoca’s CBD products.

These activities will allow the company to enter the New Zealand market with its own Australian-produced medicine range next year. THC expects product validation by the end of December.

This range will be pharmaceutical Good Manufacturing Practice (GMP) certified medicines produced from its Southport Manufacturing Facility.

THC Global’s shares are down 2.56 per cent today, with shares trading at 38 cents each as at 4:10 pm AEDT.

THC by the numbers
More From The Market Online
Saccharomyces cerevisiae yeast, 3D illustration.

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic
The Market Online Video

Little Green Pharma (ASX:LGP) reports revenue increase in Q4 FY24

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts.
Illustration representing big data technology.

Opyl forms JV with UK and US consortium to bring products to the world

Medical technology and AI company Opyl Ltd is set to form a joint venture with UK…
Ai gen brain scan

EMVision Medical successfully fabs first prototype of First Responder brain scan device – portable enough for a backpack

EMVision Medical Devices (ASX:EMV) has announced its successful fabrication of a portable on-the-spot brain scanning device.